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effectiveness of community pharmacists’ interventions in reducing
major risk factors for cardiovascular diseases. Methods: A compre-
hensive literature search from 2000 onwards was performed using
MEDLINE (1946 to June 4, 2013), EMBASE (1947 to present), CINAHL,
and Cochrane Library. The gray literature was also searched. Studies
were classiﬁed as diabetes, hypertension, dyslipidemia, and tobacco
dependence. Data abstracted from the articles included study
design/participants, study duration, key components of intervention,
primary outcome, and key ﬁndings. Study quality was assessed using
a checklist appropriate to the study design. Results: A total of 1020
citations were initially identiﬁed, with 27 meeting inclusion criteria.
Eight studies were randomized controlled trials, ﬁve were cluster
randomized trials, two were randomized before-after design studies,
ﬁve were nonrandomized controlled before-after design studies, and
seven were uncontrolled before-after design studies. Interventions
focused on diabetes (n ¼ 8), hypertension (n ¼ 9), dyslipidemiaee front matter Copyright & 2015, International S
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.1016/j.vhri.2015.03.002
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ndence to: Emmanuel Ifeanyi Chiazor, Department(n ¼ 7), and tobacco dependence (n ¼ 3). Effect sizes ranged from 7.8
to 17.7 mm Hg and from 0.2% to 2.2% reductions in systolic blood
pressure and hemoglobin A1c, respectively, while reductions in total
cholesterol ranged from 18.2 to 27.1 mg/dl. Study quality was
generally poor. Conclusions: Available evidence suggests a potential
for substantial beneﬁt in diabetes and hypertension but clinical
beneﬁts in lipid management remain unclear. The true effect of
interventions is uncertain due to poor study quality, inconsistent
results, and potential for publication bias. Further well-designed
studies are needed to determine the true impact of community
pharmacists’ interventions in reducing major risk factors for cardi-
ovascular disease.
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In the last decade, noncommunicable diseases have been
reported as major contributors to total global mortality [1,2]. Of
the estimated 57 million deaths reported worldwide in 2008,
noncommunicable diseases (predominantly cardiovascular dis-
eases [CVDs], diabetes, chronic lung diseases, and cancers)
accounted for about 36 million deaths. Of these noncommuni-
cable disease–related mortality estimates, 17.3 million deaths
were related to CVD, with coronary heart disease (CHD) account-
ing for about 7.3 million deaths and stroke for 6.2 million deaths
[3]. CVDs pose a huge public health challenge and have been
recognized by the World Health Organization as the leading
single contributor to global mortality, with low- and middle-
income countries disproportionately affected [3].
Several risk factors have been reported to be associated with
CVDs. Although some are simply nonmodiﬁable (e.g., age, sex,
family history of CVD, genetic links, and ethnicity), others aremodiﬁable. The risk of CVDs can be reduced by adopting a
healthy lifestyle such as regular physical activity, consumption
of fruits and vegetables, moderation of alcohol intake, dietary
sodium reduction, avoiding tobacco use, avoiding foods rich in
fat, and maintaining a healthy body weight [4–8]. About 80% of
CHD and CVDs are linked to behavioral risk factors [2]. The effects
of physical inactivity and unhealthy diet may present in an
individual as overweight and obesity, high blood pressure, ele-
vated blood glucose levels, and elevated blood lipid levels. These
“secondary risk factors,” which can be measured, indicate a
higher risk of developing a stroke, cardiac arrest, heart failure,
and other complications. The community pharmacy setting
presents an opportunity for health improvement because it
provides “high street” access to a trained health professional
without appointment [9]. Community pharmacies are uniquely
positioned in the heart of the community to access “hard-to-
reach” groups and hence reduce health inequalities and be
pivotal in public health improvement interventions.ociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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contact, and for some, their only contact with a health care
professional [10]. The strategic locations of the pharmacies,
extended opening hours, and ease of accessibility to the public
without need for appointment make the community pharmacy
setting uniquely suitable for implementing population-based
chronic disease prevention interventions, especially in
resource-poor settings with disproportionately high rates of
CVD morbidity and mortality [11].
In countries in which health care costs are mostly covered by
social insurance, the physicians are usually overburdened with
high demand. Where health care costs are largely paid out of
pocket at the point of service or by private insurance, a vast
majority of the population is unable to access health care
services. Therefore, the community pharmacy setting offers an
avenue to consult with a well-trained health professional, thus
either reducing the workload for primary care physicians or
offering an alternative means of access to health promotion
services for the less well-off in the society. Although the role of
community pharmacists in health promotion has been acknowl-
edged [12,13], not many studies have assessed the impact of
interventions delivered by pharmacists within the community
pharmacy setting. Although previous reviews have explored
pharmacists’ interventions to reduce risk factors for CVD, they
focused on a single risk factor [14–17], were not limited to the
community pharmacy setting [14,15,18,19], or are outdated [9].
Thus, the objectives of this study were to systematically review
the literature and assess the effectiveness of interventions
delivered within community pharmacy setting to reduce major
risk factors for CVDs.Methods
Search Strategy for the Identiﬁcation of Literature
An initial MEDLINE search was conducted to ﬁnd background
literature on community pharmacists’ activities in CVD risk
reduction. Although the area of CVD has been well researched,
the body of evidence in the ﬁeld of community pharmacy practice
is limited. This made it impractical to narrow the research to a
particular context and evidence was sought from across the
globe. The background search also aided in the identiﬁcation of
appropriate MeSH terms used in the formal search strategy,
which was conducted between July 2013 and February 2014.
Literature Search Procedure and Databases Searched
Electronic databases searched included MEDLINE (1946 to June 4,
2013), EMBASE (1947 to present), CINAHL, and Cochrane Library.
The gray literature was searched using the Cardiff University
Index to Theses database and ProQuest Dissertations and Theses.
Search terms included cardiovascular disease, coronary heart
disease, ischemic heart disease, diabetes, hypertension, dyslipi-
demia, tobacco dependence, community pharmacist(s), and com-
munity pharmacy(ies).
Eligibility Criteria
Inclusion criteria were limited to studies carried out from January
2000 onwards: studies in which interventions were delivered by a
pharmacist in a community pharmacy setting and interventions
were intended to reduce the incidence or risk of CVD; studies that
reported a clear outcome measure; articles in English language;
and articles with full text and on human studies without regard
to study design or location because generally not many published
articles exist on community pharmacy practice research. Grayliterature such as unpublished MPhil and PhD theses from 2000
onwards were also considered for inclusion.
The exclusion criteria were publications not related to com-
munity pharmacy–based interventions in preventing CVD inci-
dence or its major risk factors; publications in foreign languages,
due to the cost and time involved in translating materials; and
articles published before 2000, because studies published before
2000 were considered obsolete, more so because previous authors
highlighted that most community pharmacy practice research
was undertaken in the last decade. Review articles and studies
that focused only on economic outcomes without reporting
clinical and/or humanistic outcomes were also excluded.
Data Collation and Analysis
Study selection process
All the articles retrieved were exported to Endnote Web Reference
Management Software and duplicate records were removed. An
initial screening of titles and abstracts was conducted and those
that were not relevant to the research aim and objectives were
excluded. A more detailed review of the remaining abstracts was
undertaken to ascertain their eligibility. Full texts of potentially
eligible studies were obtained and reviewed to determine
whether they merited inclusion.
Abstraction of data
Identiﬁed articles were categorized according to the primary
outcome of interest into diabetes, hypertension, dyslipidemia,
and tobacco dependence. Data were abstracted from each study
and entered into a matrix using the following framework: ﬁrst
author, year of publication, country, and evidence grade; study
design and participants; study duration; key components of
intervention; primary outcome, and key ﬁndings. If the primary
outcome was not speciﬁed, the ﬁrst outcome reported in the
Results section was used, unless another outcome was speciﬁed
in a power calculation. The matrix was used as the basis for a
qualitative synthesis of ﬁndings and interpretation, taking into
consideration the quality of evidence.
Assessing the methodological quality of included studies
Decision on methodological quality was based on what was
reported because authors were not contacted. The quality assess-
ment framework for research is generally based on hierarchy,
with the randomized controlled trial (RCT) considered as the
“criterion standard.” The literature in the ﬁeld of community
pharmacy practice does not contain many RCTs but a substantial
number of quasi-experimental and descriptive studies.
A deliberate attempt was made to avoid the use of scoring
tools in study quality assessment for the following reasons: First,
the lack of a reference standard for total quality score forces
reviewers to make a judgment on what they consider to be an
acceptable level of quality usually on the basis of reference used
by previous authors. Second, scoring tools by implication assign
equal weight to all domains irrespective of the degree to which
the domain affects study validity. Furthermore, the question of
how such scoring instruments have been validated was
considered.
Two approaches were therefore used to assess the quality of
evidence. First, studies were stratiﬁed into RCTs and non-RCTs.
The Cochrane risk of bias tool [20] was used to assess the quality
of each RCT on the following domains: adequacy of random-
ization, allocation concealment, blinding of participants, person-
nel and outcome assessors, completeness of data, selective
outcome reporting, and “other bias.”
Consort 2010 statement [21]: extension to cluster randomized
trials (CRTs) was used to assess the quality of the included CRTs.
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Epidemiology guideline [22] for reporting cohort studies was used
to appraise the quality of included cohort studies. The Strength-
ening the Reporting of Observational studies in Epidemiology
Statement is a checklist of 22 items that has been widely used to
appraise the quality of observational studies. Thereafter, studies
were assigned an evidence grade using the evidence categories
used by the Department of Health in the National Service Frame-
works [23] (Table 1). Because of the disparity in design, inter-
vention, and outcomes that exist among studies on similar risk
factors, a meta-analysis was not performed.Results
Search Results
The search initially yielded 1020 citations; 27 met inclusion
criteria. The ﬂow diagram illustrating the sifting of literature for
review is presented in Figure. 1.
Of the 27 articles included in the review, based on the primary
end point reported, 8 studies (3 RCTs, 2 CRTs, 1 controlled and 2
uncontrolled before-after design studies) focused on diabetes
[24–31]. Nine studies (one RCT, two CRTs, three controlled and
three uncontrolled before-after design studies) focused on hyper-
tension [32–40]. Seven studies (three RCTs, one CRT, two random-
ized and one uncontrolled before-after design studies) focused on
dyslipidemia [41–47], whereas three studies (one RCT and one
controlled and one uncontrolled before-after design study)
focused on smoking cessation [48–50]. Study durations were
variable and ranged from 3 to 24 months.
Effectiveness of Interventions
Of the eight studies that focused on diabetes, 75% reported
favorable results (Table 2). Of the nine hypertension studies, six
(67%) reported favorable results in terms of lowering systolic and
diastolic blood pressure or the proportion of patients
with controlled blood pressure at the end of the study (Table 3).Table 1 – Evidence categories used by the Depart-
ment of Health in the National Service Frameworks
[23].
Evidence from research and other professional literature
A1 Systematic reviews that include at least one randomized
controlled trial (RCT), e.g., systematic reviews from
Cochrane or National Health Service Centre for Reviews
and Dissemination
A2 Other systematic and high-quality reviews that synthesize
references
B1 Individual RCTs
B2 Individual nonrandomized experimental/intervention
studies
B3 Individual well-designed nonexperimental studies,
controlled statistically if appropriate. Includes studies
using case-control, longitudinal, cohort, matched pairs,
or cross-sectional random sample methodologies, and
well-designed qualitative studies; well-designed
analytical studies including secondary analysis
C1 Descriptive and other research or evaluation not in B (e.g.,
convenience samples)
C2 Case studies and examples of good practice
D Summary review articles and discussions of relevant
literature and conference proceedings not otherwise
classiﬁedSome 71% reported favorable results out of the seven studies
that focused on lipids (Table 4), whereas all three studies on
smoking cessation reported favorable results (Table 5). Overall,
authors reported favorable results in 20 of the 27 (74%) studies,
with more favorable results reported in studies without a control
group, 86% (6 of 7), than in those with a control group, 70% (14
of 20).
Based on the primary end point reported in the studies
reviewed, pharmacists’ interventions (patient education, patient
follow-up, identiﬁcation of drug-related problems, and subse-
quent therapeutic recommendations to patient’s physician) were
considered to be effective in producing a “signiﬁcant” difference
in most of the studies; however, because of the multicomponent
nature of the intervention, it was impossible to determine
whether any intervention type was superior. Although these
results are promising, the authors’ favorable conclusions were
not supported by ﬁndings reported in at least four of the reviewed
studies [26,30,44,45].
In addition to the primary clinical outcomes, 13 studies
reported the impact of interventions on at least one humanistic
outcome (including patient knowledge, patient-reported health-
related quality of life, and patient-reported lifestyle modiﬁca-
tions). Of these 13 studies, 5 studies reported signiﬁcant improve-
ments in patient knowledge [24,27,29,37,45] and 4 studies
reported signiﬁcant improvements in patient-reported health-
related quality of life [28,32,39,46]. These favorable results relat-
ing to patient-reported health-related quality of life were not
supported by ﬁndings reported in two of the reviewed studies
[24,47]. Four studies reported signiﬁcant improvements in exer-
cise in patients [29,34,43,46]; however, Doucette et al. [26]
reported nonsigniﬁcant improvements in exercise, whereas two
diabetes studies reported signiﬁcant improvements in diet and
foot care [26,29].
Methodological Quality of Included Studies
Studies were categorized on the basis of risk factors. Some
studies had overlapping risk factors, and in such cases, classi-
ﬁcation was done on the basis of the ﬁrst primary end point
reported.
Most of the studies did acknowledge difﬁculties in recruiting
participants. Strategies generally used in recruiting participants
included identiﬁcation of potential participants from pharmacy-
held records, self-referral, or referral from physician; hence, it is
conceivable that only highly motivated patients were approached
to participate in the studies. This suggests a potential for
selection bias that could overestimate the intervention effect.
Study quality varied widely with study design and the rigor
with which the studies were conducted and reported. Random-
ized studies were rated to be of relatively higher quality than
nonrandomized designs. Without exception, every study had
potential for bias, which could potentially overestimate or under-
estimate the effectiveness of the pharmacists’ interventions
reported. Generally, study participants were not representative
of the general population of patients with the risk factor under
investigation, because in most cases, they participated voluntar-
ily in the study. More so, most of the studies recruited regular
pharmacy customers probably to ensure sufﬁcient follow-up
during the course of the study. This selected group of patients
may reﬂect a stronger interest in self-management, hence pos-
sibly resulting in positive selection bias, which could overesti-
mate effect size. It was not possible to blind participants in most
of the studies; this could potentially introduce the “Hawthorne
effect,” thus underestimating the effect size [51]. In a controlled
study, the effect size can be underestimated because the control
group can improve its performance just by virtue of participating
in a study. Most of the studies that used a randomized controlled
235 potentially relevant articles 
identified 
30 full text articles assessed for 
eligibility  
27 articles included in qualitative 
synthesis 
Excluded because: 
Title and/or abstract not relevant to study objective 
(n=785) 
Excluded because: 
Duplicate records (n=127) 
Not community pharmacy setting (n=43) 
Language other than English (n=3) 
Primary focus on attitudes/perception (n=25) 
Review articles (n=7) 
Excluded because: 
Results yet to be published (n=2) 
No clinical outcome measure reported (n=1) 
1020 citations identified from all 
sources  
Fig. 1 – Flow chart illustrating sifting of literature for review.
V A L U E I N H E A L T H R E G I O N A L I S S U E S 7 C ( 2 0 1 5 ) 9 – 2 112design were ﬂawed by small sample sizes and/or high attrition
rates, which rendered most of them underpowered [24,26,27,
38,41,42,46,48]; however, only study by Doucette et al. [26] was
insufﬁciently powered to detect signiﬁcant differences. In all, the
randomized studies provide some evidence but were not sufﬁ-
ciently robust in terms of the number of participants recruited
and how the participants were recruited; therefore, the ﬁndings
should be interpreted with caution.
Based on primary outcomes, the effectiveness of pharmacists’
interventions in diabetes was reported to be signiﬁcant in two
RCTs, two CRTs, one controlled before-after design study, and
one uncontrolled before-after design study and nonsigniﬁcant in
one RCT and one uncontrolled before-after design study.
Although uncontrolled studies provide some level of evidence,
it is difﬁcult to judge whether observed beneﬁts were truly as a
result of the intervention. Other than the study by Doucette et al.
[26], all other controlled studies revealed hemoglobin A1c (Hb A1c)
reduction ranging from 0.5% to 2.2%.
The effectiveness of pharmacists’ interventions in hyperten-
sion was reported to be signiﬁcant in one RCT and three uncon-
trolled before-after design studies and unclear in two CRTs and
three controlled before-after design studies. In the controlled
studies, effect sizes on systolic blood pressure ranged from 7.8 to
17.3 mm Hg.
Similarly, the effectiveness of pharmacists’ interventions in
lipid management was reported to be signiﬁcant in two RCTs, one
CRT study, and one uncontrolled before-after design study and
nonsigniﬁcant in one RCT, one randomized before-after design
study, and one controlled before-after design study. With the
exception of studies by Aslani et al. [42] and Paulós et al. [46], all
other studies on lipid management did not report an outcome
measure that would allow direct assessment of effect size. Aslani
et al. [42] and Paulos et al. [46] reported a reduction of 18.2 and
27.1 mg/dl, respectively (1 mg/dl ¼ 0.02586 mmol/dl), in total
cholesterol. However, it may be misleading to assess CVD risk
reduction on the basis of total cholesterol alone, making it
difﬁcult to judge the clinical beneﬁt of these observed effect
sizes. Two studies (one RCT and one controlled before-afterdesign study) on smoking cessation reported the effectiveness
of pharmacists’ interventions to be signiﬁcant. Overall, studies
suggest that pharmacists’ interventions in diabetes and hyper-
tension resulted in clinically important reductions in Hb A1c and
systolic blood pressure.Discussion
Effectiveness of Interventions
More than three-quarter of the studies that evaluated the impact
of pharmacists’ interventions on blood pressure reported statisti-
cally signiﬁcant reductions in systolic blood pressure, whereas
more than half of the studies reported statistically signiﬁcant
reductions in diastolic blood pressure. Most of the studies on
diabetes management that assessed Hb A1c as an indicator for
glycemic control reported statistically signiﬁcant reductions. The
UK Prospective Diabetes Study showed that each 1% reduction in
Hb A1c over 10 years is associated with a risk reduction of 21% for
any diabetes-related mortality, 14% for myocardial infarction,
and 37% for microvascular complications [52].
A meta-analysis of 30 clinical trials concluded that a reduction
of 5 mm Hg in systolic blood pressure lowered the risk of
cardiovascular events and stroke by 25% and 30%, respectively
[53]. Recommendations published by Izzo et al. [54] advocate that
systolic blood pressure must be the major criterion for the
management of hypertensive individuals, particularly middle-
aged and older patients. This is further supported by the seventh
report of the Joint National Committee on Prevention, Detection,
Evaluation and Treatment of High Blood Pressure [55]. Reductions
in blood pressure and Hb A1c observed in the reviewed studies are
clinically valuable, and a reduction of even 0.5% in Hb A1c is
clinically relevant.
In addition to clinical outcome measures, a number of studies
reviewed that assessed knowledge or adherence reported signiﬁ-
cant improvements in knowledge and adherence to medication
following pharmacists’ interventions. Awareness-raising
Table 2 – Characteristics and key ﬁndings of included studies on diabetes (n ¼ 8).
Reference Study design;
participants
Study
duration
Key components of pharmacist
interventions (sample size)
Description of
control group
(sample size)
Primary outcome
measure
Key ﬁndings
Ali et al. [24],
2012
RCT; patients with
type 2 diabetes
12 mo Patient education regarding diabetes
and lifestyle modiﬁcations;
monitoring of blood glucose, BP, and
BMI; medication adherence support;
identiﬁcation of DRPs; regular
follow-up; and referral to patients’
GP when appropriate (n ¼ 25)
Usual care (n ¼ 23) Change in mean
Hb A1c (%) from
baseline
Intervention: 1.6
(8.2 - 6.6)
B1 Control: 0.6
(8.1 - 7.5)
UK (P ¼ 0.001)
Correr et al. [25],
2011
Controlled before-
after design study;
patients with type
2 diabetes
12 mo Patient education regarding diabetes
and lifestyle modiﬁcations;
adherence support; identiﬁcation of
DRPs; recommend therapy change
to patients’ GP; and regular follow-
up (n ¼ 4 pharmacies; 50 patients)
Usual care (n ¼ 2
pharmacies; 46
patients)
Change in mean
Hb A1c (%) from
baseline
Intervention: 2.2
(9.9 - 7.7)
B2 Control: 0.3
(8.6 - 8.3)
Brazil (P ¼ 0.001)
Doucette et al.
[26], 2009
RCT; patients with
type 2 diabetes
12 mo Patient education regarding diabetes,
medication adherence, and self-
care behaviors; regular monitoring
of Hb A1c, LDL-C, and BP; identify
DRPs and recommend therapy
change to patients’ GP; and regular
patient follow-up and progress note
sent to physician (n ¼ 36)
Usual care (n ¼ 42) Change in mean
Hb A1c (%) from
baseline
Intervention: 0.27
(7.99 - 7.72)
B1 Control: þ0.12
(7.91 - 8.03)
USA (P ¼ 0.27)
Fornos et al. [27],
2006
RCT; patients with
type 2 diabetes
13 mo Lifestyle education; self- monitoring
of blood glucose and BP; medication
adherence support; detection of
DRPs; and referral to patients’ GP
when appropriate (n ¼ 56)
Usual care (n ¼ 58) Change in mean
Hb A1c (%) from
baseline
Intervention: 0.5
(8.4 - 7.9)
B1 Control: þ0.7
(7.8 - 8.5)
Spain (P ¼ 0.0001)
Krass et al. [28],
2007
CRT; patients with
type 2 diabetes
6 mo Patient education regarding diabetes
and lifestyle modiﬁcations;
medication adherence support;
identiﬁcation of DRPs; self-
monitoring of blood glucose; regular
Usual care (n ¼ 28
pharmacies; 159
patients)
Change in mean
Hb A1c (%) from
baseline
Intervention: 1.0
(8.9 - 7.9)
continued on next page
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Table 2 – continued
Reference Study design;
participants
Study
duration
Key components of pharmacist
interventions (sample size)
Description of
control group
(sample size)
Primary outcome
measure
Key ﬁndings
follow-up; and referral to patients’
GP when appropriate (n ¼ 28
pharmacies; 176 patients)
B1 Control: 0.3
(8.3 - 8.0)
Australia (P ¼ 0.01)
Mehuys et al.
[29], 2011
CRT; patients with
type 2 diabetes
6 mo Patient education regarding disease
and lifestyle modiﬁcations;
medication adherence support; and
identiﬁcation of drug therapy
problems (n ¼ 35 pharmacies; 153
patients)
Usual care (n ¼ 31
pharmacies; 135
patients)
Change in mean
Hb A1c (%) from
baseline
Intervention: 0.6
(7.7 - 7.1)
B1 Control: 0.1
(7.3 - 7.2)
Belgium (P ¼ 0.009)
Nau and Ponte
[30], 2002
Uncontrolled before-
after design study;
patients with type
2 diabetes
6 mo Patient education regarding diabetes
and lifestyle changes; medication
adherence support; blood glucose
monitoring; identiﬁcation of DRPs;
and recommend therapy
modiﬁcations to patients’ GP when
appropriate (n ¼ 32)
Not applicable Change in mean
Hb A1c (%) from
baseline
0.4 (7.8 - 7.4)
B3
USA (P ¼ NS)
Turnacilar et al.
[31], 2009
Uncontrolled before-
after design study;
patients with type
2 diabetes
3 mo Patient education regarding diabetes
and lifestyle changes; medication
adherence support; blood glucose
monitoring; identiﬁcation of DRPs;
and referral to patients’ GP when
appropriate (n ¼ 43)
Not applicable Proportion of
patients (%) from
baseline attaining
80–120 mg/dl BG
goal
39.5% of the patients
attained the BG
goal compared
with 16.3% at
baseline
B3
Turkey (P ¼ 0.01)
BG, blood glucose; BMI, body mass index; BP, blood pressure; CRT, cluster randomized trial; DRPs, drug-related problems; GP, general practitioner; Hb A1c, hemoglobin A1c; LDL-C, low-intensity
lipoprotein cholesterol; NS, nonsigniﬁcant.
P value for between-group comparisons of change in mean Hb A1c from baseline or within group for single-group studies.
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Table 3 – Characteristics and key ﬁndings of included studies on hypertension (n ¼ 9).
Reference Study design;
participants
Study
duration
Key components of pharmacist
interventions (sample size)
Description of control
group (sample size)
Primary outcome
measure
Key ﬁndings
Aguwa et al. [32],
2008
Uncontrolled
before-after
design study;
patients with
hypertension
5 mo Patient education regarding
hypertension, lifestyle changes,
medication adherence, and self BP
monitoring; identiﬁcation of DRPs;
regular follow-up; and referral to
patients’ GP when appropriate
(n ¼ 24)
Not applicable Change in mean BP
from baseline
SBP (mm Hg): 14.3
(158.1 - 143.8)
B3 (P ¼ 0.001)
Nigeria DBP (mm Hg): 10.8
(100.6 - 89.8)
(P ¼ 0.001)
Blenkinsopp
et al. [33], 2000
CRT; patients
with
hypertension
6 mo Patient education regarding
hypertension and lifestyle changes;
medication adherence support
(n ¼ 11)
Usual care (n ¼ 9
pharmacies)
Proportion of patients
with controlled BP at
end of study
Intervention: 78.6%
(22 of 28)
B1 Control: 45.7% (16 of 35)
UK (P value not reported for
comparison)
Chabot et al. [34],
2003
Controlled
before-after
design study;
patients with
hypertension
9 mo Using computerized decision-making
aid tool to facilitate patient
education on hypertension, lifestyle
changes, adherence support, and
recommend therapy adjustments to
physician
(n ¼ 41 patients)
Usual care (n ¼ 59
patients)
Change in mean BP
from baseline
SBP (mm Hg): Intervention:
7.8 (141.0 - 133.2)
B2
Canada
Control: þ0.5
(139.0 - 139.5)
(P ¼ 0.01)
DBP (mm Hg): Intervention:
6.5 (78.0 - 71.5)
Control: 4.0 (78.0 - 74.0)
(P ¼ 0.28)
Fikri-Benbrahim
et al. [35], 2012
Controlled
before-after
design study;
patients with
hypertension
5 mo Education regarding hypertension,
lifestyle changes, self-monitoring of
BP, and medication adherence
support; detection of DRPs; and
referral to patients’ GP when
appropriate (n ¼ 87)
Usual care (n ¼ 89) Proportion of patients
with controlled BP at
end of study
Intervention: 71.3%
compared with 52.9% at
baseline
B2 Control: 55.1% compared
with 50.6% at baseline
Spain (P ¼ 0.026)
McNamara et al.
[36], 2012
Uncontrolled
before-after
design study;
high CVD risk
score patients
6 mo Education regarding lifestyle
modiﬁcations; patient medication
review; and recommend therapy to
patients’ physician when
appropriate (n ¼ 67)
Not applicable Change in 5-y CVD risk
score (%) from
baseline
1.7 (6.8 - 5.1)
B3
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Table 3 – continued
Reference Study design;
participants
Study
duration
Key components of pharmacist
interventions (sample size)
Description of control
group (sample size)
Primary outcome
measure
Key ﬁndings
Australia (P o 0.001)
Oparah et al. [37],
2006;
Uncontrolled
before-after
design study;
patients with
hypertension
6 mo Education regarding hypertension,
lifestyle changes, BP monitoring,
and medication adherence support;
detection of DRPs; and recommend
therapy changes with patients’
physician when appropriate (n ¼ 36)
Not applicable Change in mean BP
from baseline
SBP (mm Hg): 50.5
(187.7 - 137.2)
B3 (P o 0.0001)
Nigeria DBP (mm Hg):  28.6
(117.6 - 89.0)
(P o 0.0001)
Planas et al. [38],
2009;
RCT; patients
with
hypertension
and diabetes
9 mo Education on diet and lifestyle
changes, medication review,
adherence support, and
identiﬁcation of DRPs; recommend
therapy changes to patients’ GP
when appropriate (n ¼ 32)
Usual care (n ¼ 20) Change in mean SBP
from baseline
Intervention: 17.32
(141.8 - 124.4)
B1 Control: þ2.73
(145.4 - 148.1)
USA (P ¼ 0.003)
Robinson et al.
[39], 2010
Controlled
before-after
design study;
patients with
hypertension
12 mo Education regarding lifestyle changes,
monitoring patients’ BP, medication
adherence support, and
identiﬁcation of DRPs (n ¼ 78)
Usual care (n ¼ 62) Change in mean BP
from baseline
SBP (mm Hg):
Intervention: 9.9
(151.5 - 141.6)
B2
USA
Control: 2.8
(151.5 - 148.7)
(P o 0.05)
DBP (mm Hg):
Intervention: 2.9
(82.4 - 79.5)
Control: 1.0 (87.4 - 86.4)
(P ¼ 0.16)
Zillich et al. [40],
2005
CRT; patients
with
hypertension
3 mo Education regarding hypertension and
lifestyle modiﬁcations, adherence
support, and self BP monitoring;
recommend therapy changes to
patients’ physician (n ¼ 6
pharmacies; 64 patients)
Usual care, BP
monitoring, referred
patients to GP (n ¼ 6
pharmacies; 61
patients)
Change in mean BP
from baseline
SBP (mm Hg):
Intervention: 13.4
(151.5 - 138.1)
B1 Control: 9.0
(151.6 - 142.6)
(P ¼ 0.12)
DBP (mm Hg):
Intervention: 8.8
(85.3 - 76.5)
Control: 5.6 (85.3 - 79.7)
USA (P ¼ 0.03)
BP, blood pressure; CRT, cluster randomized trial; CVD, cardiovascular disease; DBP, diastolic blood pressure; DRPs, drug-related problems; GP, general practitioner; RCT, randomized controlled
trial; SBP, systolic blood pressure.
*P value for between-group comparisons of change in mean SBP and DBP from baseline or within group for single-group studies.
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Table 4 – Characteristics and key ﬁndings of included studies on dyslipidemia (n ¼ 7).
Reference Study design;
participants
Study
duration
Key components of pharmacist
interventions (sample size)
Description of
control group
(sample size)
Primary outcome
measure
Key ﬁndings
Amariles et al.
[41], 2012
RCT; patients with
CVD or CV risk
factor
8 mo Patient education regarding
hypertension, lifestyle changes,
medication adherence, and self BP
monitoring; identiﬁcation of DRPs;
regular follow-up; and recommend
therapy changes to patients’ GP when
appropriate (n ¼ 356)
Usual care including
counseling
regarding CVD
prevention
(n ¼ 358)
Proportion of patients
achieving TC
therapeutic goal of
o200 mg/dL for
patients without
CVD or o175 mg/dL
for patients with
CVD
Intervention: þ14.1%
(42.4% - 56.5%)
B1 Control: þ5.0% (39.1%
- 44.1%)
Spain (OR 1.64; 95% CI 1.21–
2.23)
Aslani et al. [42],
2010
CRT; patients on
lipid- lowering
therapy
9 mo Provided medicine use information,
adherence support, and lifestyle
modiﬁcations; monitored total blood
cholesterol; and referred patients’ to
GP (n ¼ 9 pharmacies; 49 patients)
Usual care (n ¼ 8
pharmacies, 48
patients)
Change in mean TC
(mmol/l) from
baseline
Intervention: 0.47
(5.10 - 4.63)
Control: 0.1
(4.81 - 4.80)
B1
(P o 0.05)Australia
Blumi et al. [43],
2000
Uncontrolled
before-after
design study;
patients with
dyslipidemia
24 mo Patient education regarding CHD risks,
lifestyle modiﬁcations, medication use
review, and adherence support; blood
TC monitoring; and referral to patients’
GP (n ¼ 397)
Not applicable Change in mean TC
(mmol/l) from
baseline
TC: 30.5
(238.0 - 207.5)
B3
USA (P o 0.0001)
Eussen et al. [44],
2010
RCT; new statin
users
12 mo Patient education on drug indication,
effects, adverse effects, adherence
support, and monitoring of lipid levels
(n ¼ 513)
Usual care (n ¼ 503) Discontinuation rates
at 1 y
Intervention: 23%
Control: 26%
HR 0.84 (95% CI 0.65–
1.10)
B1
The Netherlands
Nola et al. [45],
2000
Randomized
before-after
design study;
patients with
known CAD or
lipid levels
requiring
therapy
6 mo Lifestyle education; monitoring of drug
therapy and cholesterol levels;
adherence support; and referral to
patients’ physician when appropriate
(n¼ 25)
Usual care (n ¼ 26) Change in mean risk
factor prediction
score from baseline
Intervention: 0.6
(17.0 - 16.4)
B2 Control: þ0.6
(16.5 - 17.1)
USA (P ¼ 0.05)
Paulós et al. [46],
2005
Randomized
before-after
design study;
patients with
dyslipidemia
4 mo Patient education about CVDs,
medication and lifestyle modiﬁcations,
adherence support, and identiﬁcation
of DRPs; monitoring of cholesterol
levels; and referral to patients’
physician when appropriate (n ¼ 23)
Usual care (n ¼ 19) Change in mean TC
(mg/dl) from
baseline
Intervention: 27.1
(205.1 - 178.1)
B2 (P ¼ 0.0266)
Chile Control: 1.4 (203.2 -
199.1)
(P ¼ 0.6624)
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stimulate changes in behavior and improve adherence to medi-
cation. Whether improving knowledge translates to behavior
change and better medication adherence, however, remains a
subject for debate.
The ﬁndings from the study by Doucette et al. [26] are
uncommon. Despite the improvements in healthy behaviors (diet
and exercise) reported by the intervention group, statistically
signiﬁcant reductions in clinical markers for glycemic control
were not achieved during the duration of the study. It is plausible
that patients’ diet and exercise habits improved gradually over
the course of the study and there may have not been sufﬁcient
time for these behaviors to fully induce physiological changes
that would be reﬂected in clinical markers. Furthermore, the
impact of the changes may have been too small to precipitate an
improvement in clinical markers given the small sample size of
the study. Studies of lifestyle modiﬁcations have demonstrated
that adopting healthy diet and exercise habits can improve
clinical markers such as blood pressure, Hb A1c, and low-
density lipoprotein cholesterol [56–58].
Two considerably large RCTs (Tsuyuki et al. [47] and Eussen
et al. [44]) that were rated above average in methodological
quality were still limited in their generalizability. It would be
expected that participants in an RCT should be drawn from a
representative sampling frame; however, a number of factors
present as challenge when designing and conducting an RCT in
a community pharmacy setting. In most of the trials reviewed,
only a few pharmacies gave consent to participate in the
studies; hence, potentially eligible patients who do not reﬁll
their prescriptions in these few participating pharmacies were
missed. This nonconsenting attitude could partly be explained
be ethical consideration whereby no pharmacist is willing to
deliver usual care to a patient who might beneﬁt from an
intervention. It may as well be that pharmacists are unwilling
to consent for fear of losing patients’ loyalty and patronage
should they decline consent to participate in the study. More so,
because patients reﬁll their prescriptions at any convenient
pharmacy outlet, it may be impractical to sample participants
from a more representative study population such as a General
Practice list. A careful evaluation of participants’ consent rate in
the trials reviewed showed that in most of the studies, a
considerable proportion of eligible participants were noncon-
senting. It is conceivable that patients are likely to decline
consent if informed that they may be assigned to a control
group, thereby denying them a potentially beneﬁcial interven-
tion; thus, the issue of generalizability of ﬁndings from trials
conducted in a community pharmacy setting merits some
consideration. This raises the question of how best to design a
trial in a community pharmacy setting. Several options may be
considered. To minimize the problem of contamination and
patients’ refusal, a CRT design (taking account of clustering
effect) may be worthwhile. It may also be worthwhile to adopt a
cross-over design in which case patients who originally started
off by receiving usual care also receive the intervention much
later into the study. Alternatively, the intervention may be
provided to the control group at the end of the study. This
delayed intervention design may however be limited if the study
duration is intended to be long. These techniques could poten-
tially minimize the ethical considerations that limit pharma-
cists’ participation in intervention trials.
Another aspect that warrants careful consideration is the
substantial incentives that were provided to pharmacists in the
intervention group in most of the studies. It may be worth
exploring to provide a similar incentive to pharmacists delivering
usual care to assess whether these incentives may as well result
in meaningful beneﬁts in patients’ clinical and/or humanistic
outcomes.
Table 5 – Characteristics and key ﬁndings of included studies on tobacco dependence (n ¼ 3).
Reference Study
design;
participants
Study
duration
Key components of
pharmacist
interventions (sample
size)
Description
of control
group
(sample
size)
Primary
outcome
measure
Key ﬁndings
Bock et al.
[48],
2010
Controlled
before-
after
design
study;
current
smokers
6 mo EQ group: Computerized
tool that aided
assessment of
smoking status,
counseling on
smoking-related
diseases, smoking
cessation strategies,
regular follow-up (n ¼
100); EQþ group: used
computerized tool plus
free nicotine patch (n
¼ 100)
Observation
(n ¼ 100)
7-d point
prevalence
abstinence
at 6 mo
EQþ: 28% (compared
with control; OR 3.3;
95% CI 1.9–5.2)
B2 EQ: 15% (compared
with control; OR
1.49; 95% CI 1.2–3.6)
USA OBS only: 8%
EQþ vs. EQ (Ref) (OR
2.3; 95% CI 1.5–3.9)
Khan et al.
[49],
2012
Uncontrolled
before-
after
design
study;
current
smokers
6 mo Assessed patients’
tobacco use pattern
and readiness for
change, counseling on
smoking cessation
aids, regular follow-up
(n ¼ 346)
Not
applicable
Tobacco quit
rate at 6 mo
25% quite rate was
reported after 6 mo
B3
Mexico (P value not reported)
Maguire
et al.,
2000
RCT; current
smokers
12 mo Delivered PAS
intervention, which
involved structured
counseling program on
smoking cessation,
distribution of
information leaﬂet, and
regular follow-up (n ¼
265)
Usual care
(n ¼ 219)
Self-reported
smoking
cessation at
12 mo with
cotinine
validation at
the 12-mo
follow- up
14.3% (38 of 265) of the
intervention group
was abstinent at 12-
mo follow-up
compared with 2.7%
(6 of 219) of the
control group
(P o 0.001)
B1
UK
EQ, Expert Quit; OR, odds ratio; PAS, Pharmacists’ Action on Smoking; RCT, randomized controlled trial.
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Community pharmacy practice setting presents an interesting
opportunity for delivering interventions to reduce CVD risk
factors, but a number of factors relating to the practicality of
implementing these interventions in real-life practice merit
consideration. Most of the studies reviewed reported carrying
out some form of training and reimbursed pharmacists for
delivering interventions. These potentially could have motivated
them to faithfully deliver the interventions consistently. Studies
have reported lack of time, speciﬁc training, and reimbursement
as major barriers to the delivery of pharmaceutical care inter-
ventions in community pharmacy settings [59,60], which raises
the question of to what extent are patients willing to pay for
these services.
More so, most of the interventions required the pharmacist to
regularly monitor patients’ health status by way of bloodpressure and/or blood glucose monitoring and in most cases
researchers provided patients with blood pressure and/or blood
glucose monitoring kits to encourage adherence to the research
protocol. This also raises an important real-life question of
patients’ affordability of these kits, especially in resource-poor
settings.Strengths and Limitations
The strong points of this review include the systematic way in
which evidence was sought, the evaluation of the impact of
pharmacists’ interventions on all major risk factors for CVD, and
the inclusion of different types of pharmacists’ interventions.
This study, however, should be considered in light of its
limitations. First, only full-text articles published in English were
included. There is a high chance that relevant articles were
V A L U E I N H E A L T H R E G I O N A L I S S U E S 7 C ( 2 0 1 5 ) 9 – 2 120missed because of these criteria. Although attempts were made
to search the gray literature for unpublished studies, none was
found. The authors are not conﬁdent that this study is free of
publication bias because the potential exists.
Included studies were conducted in different countries and
used different study designs. This calls for caution when inter-
preting the study ﬁndings because the issue of transferability of
ﬁndings between countries and health care systems should be
considered. Categorization of interventions and quality assess-
ment was based on what was reported in the articles, and
authors were not contacted for extra details even in cases of
ambiguity. The authors are unaware of the cost-effectiveness of
the interventions. The search term and study eligibility criteria
limited identiﬁcation of articles that focused on the cost-
effectiveness of interventions.
Furthermore, this review was not able to estimate how much
training a pharmacist needs to deliver the interventions, the
frequency with which the pharmacist has to intervene, or
whether there is an impact on CVD risk factors beyond the
period of intervention. Also, this review was unable to determine
which intervention component was more effective. This was
because interventions were multicomponent and often delivered
in combination. It is likely, however, that the combination of
improved lifestyle behaviors, better medication adherence, and
increased contact with pharmacists contributed to the observed
improvements. Again, collaboration with physicians was another
aspect of the intervention that may also have contributed to the
observed improvements. These gaps present an opportunity for
further research.Conclusions
In all the studies reviewed, interventions were generally patient
centered, physician centered, or both. Patient-centered interven-
tion involved education regarding disease state, adherence sup-
port, and regular follow-up. Physician-centered intervention
entails a collaborative working relationship with the physician
to optimize patients’ therapy.
Although study quality was generally poor, available evidence
from the results of four controlled studies that focused on
hypertension revealed a substantial reduction in systolic blood
pressure. Similar ﬁndings were observed in studies that focused
on diabetes where all but one of the controlled studies revealed
substantial clinical beneﬁts. Because all the results are in the
same direction, it suggests that there might be potential for
substantial clinical beneﬁt in hypertension and diabetes. Most of
the studies that focused on dyslipidemia did not report outcomes
that would allow for direct estimate of the potential magnitude of
impact of the intervention. The two studies that reported the
impact of the intervention on total cholesterol showed substantial
reductions. This suggests that there might be potential for sub-
stantial clinical beneﬁt in total cholesterol, but total cholesterol
alone may not be sufﬁcient to determine the impact on CVD risk.
Larger, longer, well-designed studies are needed to guide com-
munity pharmacists in this important area of practice.
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